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Accepted 8 October 2015Background. Familial hypercholesterolemia (FH) is a common autosomal dominant
disorder with a frequency of 1 in 200 to 500 in most European populations. Mutations in
LDLR, APOB and PCSK9 genes are known to cause FH. In this study, we analyzed the genetic
spectrum of the disease in the understudied Polish population.
Materials and methods. 161 unrelated subjects with a clinical diagnosis of FH from the
south-eastern region of Poland were recruited. High resolution melt and direct sequencing
of PCR products were used to screen 18 exons of LDLR, a region of exon 26 in the APOB gene
and exon 7 of PCSK9. Multiplex ligation-dependent probe amplification (MLPA) was
performed to detect gross deletions and insertions in LDLR. Genotypes of six LDL-C raising
SNPs were used for a polygenic gene score calculation.
Results. We found 39 different pathogenic mutations in the LDLR gene with 10 of them
being novel. 13 (8%) individuals carried the p.Arg3527Gln mutation in APOB, and overall the
detection rate was 43.4%. Of the patients where no mutation could be found, 53 (84.1%) had
a gene score in the top three quartiles of the healthy comparison group suggesting that they
have a polygenic cause for their high cholesterol.
Conclusions. These results confirm the genetic heterogeneity of FH in Poland, which
should be considered when designing a diagnostic strategy in the country. As in the UK, in
the majority of patients where no mutation can be found, there is likely to be a polygenic
cause of their high cholesterol level.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).Keywords:
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49M E T A B O L I S M C L I N I C A L A N D E X P E R I M E N T A L 6 5 ( 2 0 1 6 ) 4 8 – 5 31. Introduction identified variants were performed [8]. The LDL-C gene scoreFamilial hypercholesterolemia (FH) is an autosomal dominant
disorder with a frequency of 1 in 200 to 500 in European
populations [1]. It is characterized by a raised concentration of
low-density lipoprotein cholesterol (LDL-C) and high risk of
premature coronary heart disease [2].
Mutations in the LDLR gene, the APOB gene and gain-of-
function mutations in the PCSK9 gene are known to cause FH
[3]. Usually an FH-causingmutation can be found in 60–80% of
patients with a clinical diagnosis of definite FH and 20–30% of
those with possible FH [4]. In those where no causative
mutation is found, there is a strong possibility that there may
be a polygenic cause for FH [5].
In Poland, FH is an under-diagnosed conditionwith only 20%
of the cases estimated to be diagnosed to date [6]. The aim of
this study is to assess the spectrum of FH-causingmutations in
the Malopolska population in east-southern Poland.2. Methods
2.1. Subjects
161 unrelated Caucasians patients with a clinical diagnosis of
FH based on Simon Broome criteria [7] were recruited. Ethical
approval was obtained from the Jagiellonian University
Medical College Ethics Committee (KBET/34/B/2012).
2.2. Molecular Genetic Analysis
All samples were screened for mutations in all 18 exons of
LDLR gene, a fragment of exon 26 of APOB to cover
p.Arg3527Gln and exon 7 of PCSK9 to cover p.Asp374Tyr by
high resolution melt and direct sequencing of PCR products
as described in Supplementary 1. Multiplex ligation-
dependent probe amplification to detect gross deletions and
insertions in LDLR and in silico prediction of pathogenicity ofTable 1 – Baseline characteristics of the 161 participants.
Variable Total Mut
N (%) N (%
Male 55 (34.2) 26
Tendon xanthomata 92 (57.1) 43
Family history of premature CAD1 79 (49.1) 38
Personal history of premature CAD 21 (13.0) 10
On lipid-lowering medication 2 110 (68.3) 40
Mean (±SD) Mea
Age (years) 42 (17.6) 38
Maximum TC (mmol/L) 9.9 (2.6) 10.5
LDL-C (mmol/L) 3 4.8 (1.8) 5.1
HDL-C (mmol/L) 1.5 (0.3) 1.4
TG (mmol/L) 1.5 (0.8) 1.2
1 CAD = coronary artery disease.
2 At the time of study recruitment.
3 Current level.was calculated using weighted sums for six LDL-C raising
SNPs [5].
2.3. Statistical Analysis
The data were not normally distributed and log-transformed
data were used for the analysis. One-way ANOVA was used to
compare the lipid parameters and gene score between the
mutation positive and negative groups (SPSS version 21).
p Value <0.05 was used to denote significance.3. Results
3.1. Patient Characteristics
Baseline characteristics of the cohort are shown in Table 1.
Mean ± SD maximum total cholesterol (TC) was 9.9 ±
2.6 mmol/L and mean ± SD current LDL-C was 4.8 ±
1.8 mmol/L. Detailed lipid parameters of the individual
patients are shown in Supplementary 2.
3.2. Mutation Spectrum
Overall we detected a mutation in 70 out of 161 (43.4%)
patients. Mutation positive group had a significantly higher
TC level (10.5 ± 3.2 vs. 9.5 ± 2.1, p = 0.039) than mutation
negative group (Table 1). In 38 patients with a clinical
diagnosis of definite FH, we did not find a mutation. The
most frequent mutation was in APOB (p.Arg3527Gln), found in
13 (8%) patients. No patient carried the PCSK9 p.Asp374Tyr
mutation. Mutations in the LDLR gene were identified in 57
patients and accounted for the majority (81.4%) of all the
mutations found in this cohort. We identified six different
major rearrangements in 12 patients, which accounted for
17.1% of all FH causes in our cohort. Among the intronic
variants found, all were previously reported as splice-site-ation positive Mutation negative p Value
) N (%)
(37.1) 29 (31.9) 0.48
(60.6) 49 (54.4) 0.53
(53.5) 41 (45.6) 0.38
(14.1) 11 (12.2) 0.77
(57.1) 70 (76.7) 0.007
n (±SD) Mean (±SD)
(17.9) 46 (16.6) 0.004
(3.2) 9.5 (2.1) 0.039
(2.0) 4.5 (1.5) 0.046
(0.3) 1.5 (0.3) 0.223
(0.7) 1.7 (0.9) 0.001
Table 2 – LDLR and APOB variants identified in the study.
DNA level Protein level N Exon Prediction
PolyPhen SIFT Mutation
Taster
splice site
effect
LDLR gene
Major rearrangement
c.-187-?_67 + ?dup p.(?) 1 promoter-ex1 dup n/a n/a n/a n/a
c.-187-?_67 + ?del p.(?) 1 >30 kb upstream of
the promoter-ex1 del
n/a n/a n/a n/a
c.-187-?_190 + ?del p.(?) 1 promoter-ex2 del n/a n/a n/a n/a
c.941-?_1060 + ?del p.Gly314_Glu353del 1 ex7del n/a n/a n/a No
c.314-?_1186 + ?dup p.Gly396Ala;Pro106_
Val395dup
2 ex4-ex8 dup n/a n/a n/a No
c.695-?_1586 + ?del p.Val233Serfs*18 6 ex5-10 del n/a n/a n/a No
Probably pathogenic
c.100T > G p.Cys34Gly 3 2 Probably damaging Not tolerated Disease causing No
c.185C > T p.Thr62Met 1 2 Probably damaging Tolerated Disease causing No
c.380T > A p.Val127Asp 1 41 Possibly damaging Not tolerated Disease causing No
c.501C > A p.Cys167* 1 4 n/a n/a n/a No
c.530C > T p.Ser177Leu 1 4 Benign Not tolerated Disease causing No
c.654_656delTGG p.Gly219del 1 4 n/a n/a Disease causing No
c.666C > A p.Cys222* 1 4 n/a n/a n/a No
c.681C > G p.Asp227Glu 1 4 Probably damaging Not tolerated Disease causing No
c.764G > A p.Cys255Tyr 1 51 Probably damaging Not tolerated Disease causing No
c.798T > A p.Asp266Glu 1 5 Probably damaging Not tolerated Disease causing No
c.986G > T p.Cys329Phe 4 71 Probably damaging Not tolerated Disease causing No
c.1048C > T p.Arg350* 1 7 n/a n/a n/a No
c.1085delA p.Asp362Alafs*8 1 8 n/a n/a Disease causing No
c.1246C > T p.Arg416Trp 2 9 Probably damaging Not tolerated Disease causing No
c.1449G > T p.Trp483Cys 1 101 Possibly damaging Not tolerated Disease causing No
c.1567G > A p.Val523Met 1 10 benign Not tolerated Disease causing No
c.1720C > T p.Arg574Cys 1 12 Probably damaging Not tolerated Disease causing No
c.1737C > G p.Asp579Gly 3 121 probably damaging Not tolerated Disease causing No
c.1775G > A p.Gly592Glu 4 12 probably damaging Not tolerated Disease causing No
c.1834G > T p.Ala612Ser 2 121 Possibly damaging Not tolerated Disease causing No
c.1862C > G p.Thr621Arg 1 131 Probably damaging Not tolerated Disease causing No
c.1975_1987 + 16del p.(?) 1 131 n/a n/a n/a Yes
c.2026G > C p.Gly676Arg 1 14 Probably damaging Not tolerated Disease causing No
c.2032C > T p.Gln678* 2 14 n/a n/a n/a No
c.2054C > T p.Pro685Leu 1 14 Probably damaging Not tolerated Disease causing No
c.2096C > T p.Pro699Leu 2 14 Probably damaging Not tolerated Disease causing No
c.2096delC p.Pro699Argfs*10 1 141 n/a n/a Disease causing No
c.2546C > A p.Ser849* 1 171 n/a n/a n/a No
Intronic pathogenic
c.313 + 1G > A p.Leu64_
Pro105delinsSer
1 intron 3 n/a n/a n/a Yes
c.1705 + 1G > A 2 intron 11 n/a n/a n/a Yes
c.2140 + 5G > A 2 intron 14 n/a n/a n/a Yes
c.2389 + 5G > A 1 Intron 16 n/a n/a n/a Yes
Non-pathogenic
c.1171G > A p.Ala391Thr 3 8 Benign Tolerated Polymorphism No
c.1545C > T p.Asn515Asn 1 10 n/a Tolerated Polymorphism No
c.1920C > T p.Asn640Asn 1 13 n/a n/a Polymorphism No
c.1959C > T p.Val653Val 1 131 n/a n/a n/a No
c.2025C > T p.Gly675Gly 1 141 n/a n/a Disease causing No
c.2177C > T p.Thr726Ile 2 15 Benign Tolerated Polymorphism No
c.2231G > A p.Arg744Gln 1 15 Benign Tolerated Polymorphism No
c.2390-16G > A Intronic 3 intron 17 1 n/a n/a n/a No
APOB gene
c.10580G > A p.Arg3527Gln 13 APOB ex26 Probably damaging Not tolerated n/a n/a
1 Novel; n/a = not applicable.
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Fig. 1 – Family co-segregation of the novel c.1862C > G (p.Thr621Arg) LDLRmutation. (A) A family pedigree of the index patient
(F1) with the novel mutation including age (years), TC level (mmol/L) and LDL-C level (mmol/L). Five members of the family (F2,
F3, F4, F5 and F6) were screened and sequenced for the mutation. Only F4 was found to carry the novel variant as the index,
which co-segregated with FH phenotype. (B) LDLR exon 13 sequencing for the index patient (appropriate base arrowed), (C)
Wild type exon 13 sequence.
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genic (www.ucl.ac.uk/ldlr) except c.2390-16G > A which is not
near to the splice site; thus, based on prediction tools it was
designated as non-pathogenic.
We also identified 13 LDLR variants that were consid-
ered non-pathogenic. Seven of these variants were pres-
ent in patients already identified with a pathogenic
mutation (Table 2).
3.3. Novel Mutations
We found 10 novel mutations in the LDLR gene (Table 2). The
mutation c.1975_1987 + 16del, is predicted to delete the last
four amino acids of exon 13 and the consensus splice site, and
is predicted to result in a frame shift. Themutation c.2096delC
will also result in a frame shift in exon 14 (p.Pro699Argfs*10)
and would be pathogenic. The mutations p.Cys255Tyr and
p.Cys329Phe, would cause loss of cysteine in the ligand
binding domain of the LDL-receptor and cause aberrant
protein folding. The mutation p.Ser849* causes a premature
stop codon at position 849 in the cytoplasmic tail of LDL-
receptor, known to be important for the localisation of the
receptor in coated pits on the cell surface.
We predict that the novel mutation (p.The621Arg) would
cause aberrant recycling of the LDL-receptor protein to the
cell surface and is thus pathogenic. Analysis of the
proband’s family members showed that this mutation
segregated with the disease. From five family members,
the daughter was found to have a raised TC level
(10.7 mmol/L) and LDL-C level (8.1 mmol/L) and inherited
the p.Thr621Arg mutation. The index father, who had
raised serum cholesterol levels, died of myocardial infarc-
tion at the age of 46 (Fig. 1).
The other four novel mutations, p.Ala612Ser, p.Asp579Gly,
p.Trp483Cys, and p.Val127Asp were also predicted to be
pathogenic; however family members of these patients were
not available for segregation analysis.3.4. LDL-C Gene Score
Genotypes for all six SNPs were obtained for 101 patients.
Compared to the control group mean ± SD score (0.63 ± 0.22),
the mutation negative patients had the highest LDL-C score
(0.68 ± 0.21), followed by the mutation positive patients
(0.67 ± 0.21). Following the previously reported trend [5], as
expected for a sample of this size, none of these SNP score
differences were statistically significant (Fig. 2). Using the
control cohort SNP score quartiles, out of the 63 genotyped
mutation negative FH patients, 53 (84.1%) had a SNP score
above the bottom quartile (>0.51) and therefore the cause of
high LDL-C in these patients is likely to be polygenic.4. Discussion
In this cross-sectional genetic study, we had an overall FH
mutation detection rate of 43.4%. This finding is in agreement
with previous studies of European populations [9], and similar
to that reported in the UK [4,10]. Approximately 30% of
patients with a raised LDL-C level (42.9% of mutation positive
and 23.3% of mutation negative) were not on any lipid-
lowering medication at the time of recruitment due to their
first attendance to lipid clinic for initiation of lipid-lowering
drug, statin intolerance or pregnancy. The significantly higher
cholesterol levels in monogenic group are likely to be
attributed to presence of genetic mutation.
The spectrum of LDLRmutations in Europe varies between
countries, from Greece with only six mutations responsible
for causing FH in 60% of the cases, to Netherlands with the
most heterogeneous spectrum [11,12] and to the UK with over
200 different mutations [13]. We found 39 different FH
mutations in a cohort of 161 patients, which suggests a
broad spectrum of mutations and high heterogeneity of FH in
Poland. The most common APOB mutation in European
Fig. 2 – LDL-C genetic risk score analysis based on a 6-SNP score (Futema et al. 2015). Genotypes for 6 LDL-C-associated SNPs
were available for 91 out of 101 studied FH patients. For additional nine patients with a one missing APOE genotype we
assumed that they had the E3E3 isoform (the most common). One more patient had a missing rs6511720 genotype and we
assumed that the patient did not have the risk allele for this SNP. The highest mean score (standard deviation (SD)) was
observed in individualswith the clinical diagnosis of FHwhere nomutation detected (0.68 (±0.21)). Individuals from the control
cohort (WHII) had the lowest mean score (SD) (0.63 (±0.22)), whereas those with a confirmed FH mutation had intermediate
score (0.67 (±0.21)). The differences between the FH patients and the control did not reach a statistical significance.
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patients [14]. We found this mutation in 8% of the patients in
south-eastern part of Poland, which is similar to that reported
in the northern part of Poland [15,16]. The frequency of large
insertion/deletions was also higher than in a recently
reported UK sample (16.7% vs. 10%) [8]. These findings
highlight the importance of including the APOB gene and
large LDLR gene rearrangements tests in the mutation
screening of Polish people.
We found ten novel pathogenic mutations in the LDLR
gene based on multiple prediction algorithms and demon-
strated co-segregation of the novel mutation p.Thr621Arg
with the FH phenotype. We also described the novel mutation
of p.Cys329Phe in a previous report [17]. In our study, the
mean weighted LDL-C raising SNPs gene score for patients
without a mutation was higher than the control group as was
shown in previous studies in Europe [5,18]. In patients where
no mutation was found, 84.1% had a gene score in the top
three quartiles of the score based on the healthy comparison
group, suggesting that they have a polygenic cause for their
high cholesterol levels. By contrast, in the remaining 10
mutation-negative patients who were found to have a low
SNP score (in the bottom quartile), it is likely that there is a
singlemutation in a region of the LDLR, APOB and PCSK9 genes
not examined here, or there might be amutation in a yet to bediscovered gene. Further family studies and use of more
comprehensive next generation sequencing methods in these
patients may help to distinguish these possibilities.
There are limitations to our study. We had a small number
of samples and we only examined the regions of APOB and
PCSK9 where the most common FH-causing mutations occur.
Also due to lack of consent, we could not perform co-
segregation in all patients with novel variants.
The scale of FH under-diagnosis in Poland has been
recently highlighted [6,19] and, as in other European coun-
tries, there is an urgent need for a national management plan
and an efficient mutation testing strategy in Poland.Author Contributions
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